Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy

Research output: Contribution to journalArticlepeer-review

Abstract

Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment.

Original languageEnglish (US)
JournalMolecular imaging
Volume16
DOIs
StatePublished - Jul 5 2017

Keywords

  • PD-1
  • PET
  • SPECT
  • atezolizumab
  • immunotherapy
  • optical imaging
  • peptide

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Biomedical Engineering
  • Radiology Nuclear Medicine and imaging
  • Condensed Matter Physics

Fingerprint

Dive into the research topics of 'Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy'. Together they form a unique fingerprint.

Cite this